Cellectar Biosciences Inc... (CLRB)
Cellectar Biosciences Statistics
Share Statistics
Cellectar Biosciences has 46.08M shares outstanding. The number of shares has increased by 28.54% in one year.
Shares Outstanding | 46.08M |
Shares Change (YoY) | 28.54% |
Shares Change (QoQ) | 11.66% |
Owned by Institutions (%) | 0% |
Shares Floating | 45.31M |
Failed to Deliver (FTD) Shares | 7.67K |
FTD / Avg. Volume | 0.46% |
Short Selling Information
The latest short interest is 1.84M, so 4.45% of the outstanding shares have been sold short.
Short Interest | 1.84M |
Short % of Shares Out | 4.45% |
Short % of Float | 4.58% |
Short Ratio (days to cover) | 8.34 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -0.38. Cellectar Biosciences's PEG ratio is 0.
PE Ratio | -0.25 |
Forward PE | -0.38 |
PS Ratio | 0 |
Forward PS | 0.3 |
PB Ratio | 0.77 |
P/FCF Ratio | -0.23 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cellectar Biosciences.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.
Current Ratio | 2.58 |
Quick Ratio | 2.58 |
Debt / Equity | 0.03 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.01 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-4.05M |
Employee Count | 11 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 66K |
Effective Tax Rate | -0.15% |
Stock Price Statistics
The stock price has increased by -92.2% in the last 52 weeks. The beta is 0.67, so Cellectar Biosciences's price volatility has been higher than the market average.
Beta | 0.67 |
52-Week Price Change | -92.2% |
50-Day Moving Average | 0.31 |
200-Day Moving Average | 1.41 |
Relative Strength Index (RSI) | 39.97 |
Average Volume (20 Days) | 1.68M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -51.78M |
Net Income | -44.58M |
EBITDA | -51.78M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.22 |
Balance Sheet
The company has 23.29M in cash and 494K in debt, giving a net cash position of 22.79M.
Cash & Cash Equivalents | 23.29M |
Total Debt | 494K |
Net Cash | 22.79M |
Retained Earnings | -247.34M |
Total Assets | 25.47M |
Working Capital | 14.86M |
Cash Flow
In the last 12 months, operating cash flow was -47.58M and capital expenditures -104.19K, giving a free cash flow of -47.69M.
Operating Cash Flow | -47.58M |
Capital Expenditures | -104.19K |
Free Cash Flow | -47.69M |
FCF Per Share | -1.3 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CLRB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for CLRB is $28, which is 9555.2% higher than the current price. The consensus rating is "Buy".
Price Target | $28 |
Price Target Difference | 9555.2% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 22, 2022. It was a backward split with a ratio of 1:10.
Last Split Date | Jul 22, 2022 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -18.89 |
Piotroski F-Score | 1 |